Sophiris Bio Inc (SPHS) was Initiated by ROTH Capital to “Buy” and the brokerage firm has set the Price Target at $8. ROTH Capital advised their investors in a research report released on Sep 15, 2016.
Many Wall Street Analysts have commented on Sophiris Bio Inc. Piper Jaffray Initiated Sophiris Bio Inc on Aug 30, 2016 to “Overweight”, Price Target of the shares are set at $7.Company shares were Reiterated by Maxim Group on Aug 10, 2016 to “Buy”, Firm has raised the Price Target to $ 6 from a previous price target of $4 .
Sophiris Bio Inc opened for trading at $2.77 and hit $2.94 on the upside on Wednesday, eventually ending the session at $2.85, with a gain of 1.42% or 0.04 points. The heightened volatility saw the trading volume jump to 843,375 shares. Company has a market cap of $64 M.
In a different news, on Jan 23, 2015, Lars Ekman (director) sold 9,663 shares at $0.47 per share price.
Sophiris Bio Inc. formerly Protox Therapeutics Inc. is a Canada-based biopharmaceutical company focused on the research development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate PRX302 which has completed three clinical trials for the treatment of BPH as well as two clinical trials for the treatment of localized recurrent prostate cancer.